One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 3.6 million shares of Syros Pharmaceuticals Inc. (NASDAQ: SYRS) on Wednesday, as the share price of this fund traded up nearly 2% in the day’s session. The fund’s share price has greatly improved over the past year.
ARK Innovation ETF (NYSEARCA: ARKK) sold 3,574,908 shares of Syros Pharma. At Wednesday’s closing price, this would have valued this sale at roughly $20.0 million. This is only a small fraction of the total holdings. ARKK is up 81% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKF | 6060HK | ZHONGAN ONLINE P&C INSURANCE CO LTD | 677,300 |
| ARKF | GWRE | GUIDEWIRE SOFTWARE INC | 246 |
| ARKG | GH | GUARDANT HEALTH INC | 10,800 |
| ARKG | NVS | NOVARTIS AG | 166,980 |
| ARKG | PSTI | PLURISTEM THERAPEUTICS INC | 50,671 |
| ARKG | TAK | TAKEDA PHARMACEUTICAL CO LTD | 78,202 |
| ARKK | SYRS | SYROS PHARMACEUTICALS INC | 3,574,908 |
| ARKK | ONVO | ORGANOVO HOLDINGS INC | 8,989 |
| ARKK | HUYA | HUYA INC | 486,140 |
| ARKQ | AVAV | AEROVIRONMENT INC | 11,207 |
| ARKQ | GLEO | GALILEO ACQUISITION CORP | 22,423 |
| ARKQ | ADSK | AUTODESK INC | 119 |
| ARKX | RAVN | RAVEN INDUSTRIES INC | 9,215 |
| ARKX | ADSK | AUTODESK INC | 23 |
| ARKX | WKHS | WORKHORSE GROUP INC | 6 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St., owner of a673b.bigscoots-temp.com.
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
